How much is the latest market price of zotuximab for injection?

Zolbetuximab (zolbetuximab-clzb)-VYLOY is an innovative targeted antibody drug, mainly used to treat CLDN18.2-positive, HER2-negative advanced gastric cancer or gastroesophageal junction adenocarcinoma. As a targeted drug based on precise molecular markers, its clinical value has been recognized in the European, American and Japanese markets, and is gradually being promoted globally. The price of this drug has always been the focus of attention, especially as the original drug in China has just been launched. Clinicians and patients are eager to understand its market pricing and acquisition methods.

Although zotuximab has been launched as an original drug in China, due to its short time on the market, it has not yet been included in the national medical insurance catalog. Therefore, patients still need to pay for its use. According to public information and overseas drug price calculations, without being included in medical insurance, the price of a 100mg tube of zotuximab may be more than 7,000 yuan. The specific price will be affected by multiple factors such as import channels, exchange rate changes, tariffs and distribution costs. In the U.S. and European markets, the drug is usually provided through specialty pharmacies or cancer centers and is administered according to body weight or body surface area. The dosage required for each treatment varies greatly, which also directly affects the final cost of the treatment. Taking standard adult patients as an example, a single medication often requires multiple medications, and the cost of the entire treatment cycle can reach tens of thousands of yuan or even higher.

Since there are currently no generic versions of this drug on the market, its supply still relies entirely on the original manufacturer, so it still faces challenges in terms of price control and accessibility. According to overseas drug databases, zotuximab is currently only approved for use in some developed countries, and its sales price is generally high. It belongs to the high-end antibody drug series. For domestic patients, whether to enter the medical insurance directory will directly affect its breadth of use and affordability, which is also a common focus of the industry and patient groups.

Reference materials:https://www.astellas.com/en/news/29401